Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Patients with Malignant pleural effusion can be diagnosis advanced cancer. Currently
recognized as the most reliable method to control malignant pleural effusion is pleural fixed
or thoracic catheter drainage. The most effective pleural fixed agent is pulvis talci, but
there are about 30% relapse rate. Thoracic drainage can lead to some complications, such as
chest infections, catheter migration and blockage etc. The investigators need a reliable
methods to solve dyspnea and other symptoms caused by malignant pleural effusion, and improve
quality of life. The purpose of this study was to determine the efficacy and Safety of
intrapleural Bevacizumab versus pulvis talci as treatment for malignant pleural effusions
(MPE) in patients.